EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long‐Term Dupilumab Efficacy and Safety in Pediatric Patients: A Real‐World Experience Over 2 Years

Daniele Omar Traini, Cristina Guerriero, Giulia Coscarella, Lorenzo Maria Pinto, Niccolò Gori, Gerardo Palmisano, Ketty Peris

Dermatologic Therapy · 2025-01 · 2025 (1)

DOI: 10.1155/dth/4857510 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 14.10.2025. Verfasst von Daniele Omar Traini und 6 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this exploratory retrospective, single‐center observational study, we evaluated the long‐term effectiveness and safety of dupilumab in 42 pediatric patients with moderate‐to‐severe atopic dermatitis (AD), including individuals with rare genetic syndromes. We also explored the feasibility of seasonal dosing modulation. During the summer months (June–August), patients underwent an extended dupilumab dosing interval (from every 2 weeks to every 3 weeks or from every 4 weeks to every 5 weeks), taking advantage of the typical seasonal improvement in AD symptoms. At 24 months, mean EASI scores were significantly reduced from 21.2 at baseline to 1.6 ( p < 0.0001), and substantial improvements were observed in both P‐NRS and sleep quality, with 95% of patients achieving at least a 50% improvement by week 16. Although the summer dosing extension maintained disease control in all patients, 21 (50%) required a return to standard dosing in autumn to sustain efficacy. Dupilumab was well‐tolerated, with conjunctivitis being the sole adverse event, reported in 9.5% of patients and resolving without the need to discontinue therapy. These results underscore dupilumab’s sustained efficacy and safety in a complex pediatric population and support the potential of seasonal dose modulation as a tailored treatment strategy.

Zitieren

APA

Traini, D. O., Guerriero, C., Coscarella, G., Pinto, L. M., Gori, N., Palmisano, G., & Peris, K. (2025). Long‐Term Dupilumab Efficacy and Safety in Pediatric Patients: A Real‐World Experience Over 2 Years. Dermatologic Therapy, 2025(1). https://doi.org/10.1155/dth/4857510

Vancouver

Traini DO, Guerriero C, Coscarella G, Pinto LM, Gori N, Palmisano G, et al. Long‐Term Dupilumab Efficacy and Safety in Pediatric Patients: A Real‐World Experience Over 2 Years. Dermatologic Therapy. 2025;2025(1). doi:10.1155/dth/4857510

BibTeX
@article{Traini2025,
  author = {Traini, Daniele Omar and Guerriero, Cristina and Coscarella, Giulia and Pinto, Lorenzo Maria and Gori, Niccolò and Palmisano, Gerardo and Peris, Ketty},
  title = {Long‐Term Dupilumab Efficacy and Safety in Pediatric Patients: A Real‐World Experience Over 2 Years},
  journal = {Dermatologic Therapy},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/dth/4857510}
}
Kostenlos starten →